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Summary The past 10 years have been an exciting
ride for Chronic Lymphocytic Leukemia (CLL) afi-
cionados. An overview of changes in management
paradigms in CLL, ranging from insights into biol-
ogy, via chemotherapy and chemoimmunotherapy to
maintenance and novel drugs will be presented.
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The path to chemoimmunotherapy
The 10 year anniversary of a journal is not only a rea-
son for celebration, but also provides an opportunity
to assess progress in the field over a longer period of
time. In our clinical world of incremental improve-
ments, this is a relatively rare opportunity to reflect
on what has happened on a larger scale than usual
and determine how happy or hopeful that leaves us.
About 10 years ago, the CLL field had just left the
stage where CLL was treated with chlorambucil (CLB)
monotherapy or lymphoma polychemotherapy with
limited success for the aggressive variants of CLL for
decades. Resurrecting CLL from being the “boring”
leukemia, the field developed very relevant dynamics
([1]; Fig. 1). At the turn of the millennium, important
biological insights, such as the recognition of recur-
rent FISH cytogenetic lesions [2], which had a very
relevant prognostic impact, or the definition of two bi-
ologically distinct groups of CLL, i. e., those with mu-
tated and unmutated IgVH status [3, 4] and again very
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different clinical behavior, were gained. Also, more ef-
fective chemotherapy backbones were proposed and
a combination of fludarabine and cyclophosphamide
(FC) had been shown to produce better responses and
longer PFS in a number of randomized trials [5, 6].
However, none of these trials produced anoverall sur-
vival (OS) benefit. In these trials, it also became clear
that the proposed FISH cytogenetic groups were able
to define subgroups withmuch worse performance af-
ter chemotherapy induction. Thus, del17p and del11q
were defined as risk factors with predictive proper-
ties towards treatment outcome. At that time, MD
Anderson pioneered the use of rituximab in a com-
bination with FC in their typical phase 2 cohort de-
sign [7, 8]. Indeed, this combination produced su-
perior outcomes in indirect comparison with histori-
cal controls from MD Anderson itself. A little while
into the decade, reviewed here, these monocentric
data received randomized support from the German
CLL 8 trial [9]. This trial not only showed the expected
increase in responses and progression-free survival
(PFS) for adding the antibody to FC, but was able to
define an overall survival benefit for the first time in
CLL, thus, changing the standard of care for patients
fit to tolerate this intensive regimen. An additional ex-
citing observation from the trial was that patients with
del11q (a high-risk group for early failure with fludara-
bine monotherapy) benefitted substantially from the
FCR combination [10].
The hunt for remission depth
Around the same time, measurement of residual tu-
mor mass—derived either by PCR-based or flow-
cytometric methods [11]—showed that patients that
had achieved high quality remissions, as defined by
these measurements, showed very long remission du-
ration. Initial observations of such minimal residual
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Fig. 1 Development of
licensed (dark pink) and unli-
censed (light pink) treatment
options for CLL over a rough
timeline. Thequestion mark
highlights the possibility
that the field may move to
chemotherapy-free options.
Abbreviations are mainly





















disease (MRD)-negative states were available from
alemtuzumab-treated patients [12]. This very effec-
tive antibody was an exciting player at the start of
our memo decade, but has since fallen by the wayside
due to crippling toxicities and management deci-
sions for the drug. However, it remained unclear in
phase 2 trials whether the achievement of MRD neg-
ativity was merely a sign of “good” risk disease and,
thus, associated with superior response or whether
it might develop into an independent treatment goal
that one could strive to achieve. The concept of MRD
as a treatment goal has, indeed, had more staying
power than alemtuzumab. In fact, the already men-
tioned CLL 8 trial had extremely interesting results
in this respect [13]: as expected, patients achieving
MRD negativity (i. e., <10–4 CLL cells) as measured
by flow cytometry had significantly longer PFS. This
turned out to be independent of the treatment arm,
but it became clear that the addition of rituximab
was able to roughly double the number of patients
achieving MRD negativity, thus, suggesting that re-
mission depth could be an independent treatment
goal. Consequently, a number of trials tested whether
one could devise more effective treatments, produc-
ing higher rates of deep remissions by intensifying
therapy. The addition of additional chemotherapy
agents (e. g., mitoxantrone) [14] or antibodies (e. g.,
alemtuzumab) [15] to an FCR backbone was thus
tested. The results were, however, relatively disap-
pointing: in the highest risk groups results could not
be improved significantly, generating some sort of
response plateau. Furthermore, and, equally impor-
tantly, the trials demonstrated significantly increased
toxicity. With the perspective that FCR was targeted at
very fit CLL patients and an option that was already
too toxic for a majority of patients with CLL, these
escalation trials were, thus, not producing a benefit
for a relevant group of patients. Thus, the hunt for
MRD negativity took a hit.
Tailoring treatment intensity and duration
Indeed, a parallel approach to preserve the efficacy
of the antibody effects, while reducing the toxicity
of chemotherapy backbones, led to the definition
of therapeutic options with less intensity than FCR.
Combining rituximab with bendamustin (RB) showed
encouraging efficacy in phase 2 trials [16], while seem-
ing much less toxic. A randomized comparison (the
German CLL 10 trial) [17] was able to confirm this
lower toxicity profile of the regimen in fit patients,
but showed that the reduction of toxicity came at
a price of somewhat reduced efficacy. However, the
efficacy benefit of FCR in the trial was not detected in
the older patients in the trial. In parallel, the toxicity
difference was also very prominent in the older, but
fit population. This suggested that for an older or
possibly less fit population, RB may have a better
risk/benefit ratio than FCR, while maintaining rele-
vant disease control. Parallel approaches in less fit
patients showed that the addition of a CD20 antibody
(either of rituximab, ofatumumab, or obinutuzumab)
[18, 19] was able to improve responses and PFS, and,
in the case of obinutuzumab, also a benefit in overall
survival. Thus, within a few years after the launch of
memo, the landscape of treatment in CLL was turned
over with the introduction of chemoimmunother-
apy regimens that could be tailored to individual
tolerability. Since then, a number of approaches to
investigate remission maintenance strategies after
chemoimmunotherapy induction have been investi-
gated and an improvement of PFS by maintenance
with two different CD20 antibodies has been reported
in full papers [20, 21]. Similar improvements with
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lenalidomide maintenance strategies have recently
been presented at ASH 2016. None of the trials have
been able to report OS benefits for maintenance
strategies, but this may be due to short follow-up
and/or improved salvage therapies. In fact, we may
not be able to fully resolve these questions in the
future, given the changes in the field that dominated
the last years of the memo decade.
The development of novel treatment paradigms
All the developments described so far had left the
highest risk patients—those with del17p and p53 dys-
functions—almost untouched. These patients who
had low response rates and short PFS even with in-
tensive induction treatment options, such as FCR. The
only patients in this group who were able to achieve
longer survival were in the small group of CLL patients
who qualify for allogeneic transplant [22]. Some suc-
cess in this group had been reported for alemtuzumab
therapies (e. g., in combination with high-dose corti-
costeroids and at a high price regarding infections),
but that was swept away by things to come.
In parallel to the increase in interest in treating CLL,
there was a surge in understanding of the disease bi-
ology. Importantly, it became clear that CLL was not
merely genetically programmed to proliferate and sur-
vive, but relied extensively on microenvironmental in-
teractions for these outcomes [23]. It thus became
clear that there would be signaling pathways that pro-
vide essential signals for the development of CLL and
that these signaling pathways may serve as important
targets for the development of treatment. The kinase
inhibitors ibrutinib and idelalisib, targeting compo-
nents involved in the B cell receptor signaling cas-
cade, both showed very interesting phenomenology
of response [24, 25]. In fact, both drugs were able to
rapidly shrink lymph node masses even in massively
pretreated patients (a feat that chemoimmunotherapy
has very big problems with). However, apparently
the inhibitors did not kill the CLL cells rapidly, but
rather spilled them from the lymph nodes (and bone
marrow) into the peripheral blood, where a some-
times dramatic increase in lymphocytosis could be
observed. This lymphocytosis then decreases over
time and the drugs produce a very high rate of par-
tial, but durable remissions under continuing treat-
ment. Also there is a clear tendency for improve-
ment of response qualities over time. Complete remis-
sions, or even MRD negativity, however, remain rare.
Thus, the currently used treatment paradigm for these
drugs is to treat until progression. The tolerability of
the drugs is good compared with chemoimmunother-
apy, but both substances have a distinct set of rare
side effects that mandate specific management. Ex-
citingly the control of clones with functional p53 de-
ficiency by these drugs is much better than with stan-
dard treatment, giving this subgroup important av-
enues to improved survival [26, 27]. However, with
longer observation times the impression is that pre-
treated and/or p53 deficient CLL has a steady rate of
relapse even from these treatments [28]. Thus, al-
ternatives are still needed. Most recently, direct tar-
geting of the cell death machinery, via the Bcl-2 spe-
cific “BH3-mimetic” venetoclax has entered the field.
Venetoclax produced relevant disease control in pre-
treated patients and in patients with del17p, adding
another option to the armamentarium [29]. Impor-
tantly, venetoclax was effective in patients previously
treated with kinase inhibitors, giving those patients
a salvage option (only presented in abstract form so
far). In initial experience, venetoclax led to a high rate
of relevant tumor lysis syndromes, but since a slow
ramp up of the dose has been mandated this has not
proven to be a big problem. Outside of the spectrum
of currently licensed options, there are highly relevant
developments in the area of immunomodulation (e. g.,
lenalidomide) [30, 31] and immunotherapy (e. g., CAR
T cells) [32] that need to be mentioned but cannot be
discussed in the brevity of the overview.
We have, thus, arrived at an exciting moment in
CLL history, with lots of options to develop in the fu-
ture and quite a bit of uncertainty about the optimal
treatment pathways of today and tomorrow. As com-
bination approaches with novel drugs are in develop-
ment, we face the tangible possibility of cure or very
long-term control for our patients. This has clearly
been a very exciting decade for those interested in
CLL, leaving the community both happy and hopeful.
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